EUVIMEDOpdag EUVIMED
Klinische Studie (Phase I)Randomisierte kontrollierte Studie

Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects

Zhili Jin, Jingxuan Wu, Jiaqi Liang, Jing Yang, Qing Sheng, Zhen Liu, Yan Wang, Cong Zhu, Xipan Liu, Wenheng Liang, Xiaobin Zhang, Yaoyu Chen and 6 more

British Journal of Pharmacology · 2026-06 · 183 (11) · 3074-3092

DOI: 10.1111/bph.70338 ↗

At a glance

Klinische Studie (Phase I) in British Journal of Pharmacology, published online on 2026-02-23. Written by Zhili Jin and 17 co-authors. Institution: Beijing Friendship Hospital, Capital Medical University, Beijing, China. Major MEDLINE topics: TYK2 Kinase, Protein Kinase Inhibitors, Food-Drug Interactions, Pyridazines. 29 references. Funded by: Natural Science Foundation of Beijing Municipality, National Key Research and Development Program of China, Capital's Funds for Health Improvement and Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Tyrosine kinase 2 (Tyk2) inhibitors hold therapeutic promise for patients with inflammatory conditions driven by interleukin (IL)‐12/23 signalling. ARTS‐011 [6‐(cyclopropanecarboxamido)‐4‐((2‐methoxy‐3‐(3‐methyl‐1 H ‐1,2,4‐triazol‐1‐yl)phenyl)amino)‐N‐(methyl‐d 3 )pyridazine‐3‐carboxamide] is a novel chemical agent that acts as a small‐molecule allosteric inhibitor of Tyk2, selectively targeting the JH2 domain of the Tyk2 protein. A first‐in‐human, single and multiple ascending dose (SAD and MAD) clinical study was conducted to evaluate the tolerability, safety, pharmacokinetic profile and food effects of the Tyk2 inhibitor ARTS‐011. Experimental Approach This study is registered at ClinicalTrials.gov under the identifier NCT06260527. The study consisted of three parts: ‐ Part A was a SAD cohort and Part B was a MAD cohort both conducted in Chinese healthy subjects, using a randomized, double‐blind, placebo‐controlled design. Part C was a randomized, open‐label, two‐period, crossover study designed to investigate the food effects on ARTS‐011. Key Results Single oral doses ranging from 3 to 60 mg and multiple oral doses ranging from 10 to 40 mg of ARTS‐011 demonstrated favourable safety and tolerability profiles in healthy subjects. Furthermore, ARTS‐011 was well‐tolerated under both fasting and fed conditions following a single 20 mg dose. The 90% confidence interval of the geometric mean ratio of area under the concentration‐time curve (AUC) fell entirely within the bioequivalence criteria (80.00%–125.00%), indicating no food effect on AUC. Conclusion and Implications ARTS‐011 is a promising oral Tyk2 inhibitor with an acceptable safety profile and potential for once‐daily dosing. These results support further clinical development of ARTS‐011 in patients with inflammatory and autoimmune diseases.

Subjects

MeSH terms (MEDLINE)

TYK2 KinaseProtein Kinase InhibitorsFood-Drug InteractionsPyridazinesTriazolesHumansMaleAdultYoung AdultFemaleDouble-Blind MethodDose-Response Relationship, DrugAdministration, OralArea Under CurveTyrosine Kinase Inhibitors

Author keywords

JH2 Pseudokinase domainTyk2 inhibitorfirst‐in‐humanpharmacokinetic profilesafety

Substances

TYK2 KinaseProtein Kinase InhibitorsPyridazinesTYK2 protein, humanTriazolesTyrosine Kinase Inhibitors

Authors and institutions

  • Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Anrui Biomedical Technology Co, Guangzhou, China.
  • Allorion Therapeutics Inc, Natick, Massachusetts, USA.

Funding

  • Natural Science Foundation of Beijing Municipality
  • National Key Research and Development Program of China
  • Capital's Funds for Health Improvement and Research
  • National Basic Research Program of China

Cite

APA

Jin, Z., Wu, J., Liang, J., Yang, J., Sheng, Q., Liu, Z., Wang, Y., Zhu, C., Liu, X., Liang, W., Zhang, X., Chen, Y., Li, J., Song, Y., Wu, X., Chen, J., Ji, T., & Dong, R. (2026). Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects. British Journal of Pharmacology, 183(11), 3074-3092. https://doi.org/10.1111/bph.70338

Vancouver

Jin Z, Wu J, Liang J, Yang J, Sheng Q, Liu Z, et al. Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects. British Journal of Pharmacology. 2026;183(11):3074-3092. doi:10.1111/bph.70338

BibTeX
@article{Jin2026,
  author = {Jin, Zhili and Wu, Jingxuan and Liang, Jiaqi and Yang, Jing and Sheng, Qing and Liu, Zhen and Wang, Yan and Zhu, Cong and Liu, Xipan and Liang, Wenheng and Zhang, Xiaobin and Chen, Yaoyu and Li, Jiangshuo and Song, Yuqin and Wu, Xiaofang and Chen, Jingcheng and Ji, Tao and Dong, Ruihua},
  title = {Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {11},
  pages = {3074--3092},
  doi = {10.1111/bph.70338}
}
Start for free →